(Q43075872)

13 November 2017

Cannabis and Cannabinoids for Chronic Pain (English)

1 reference

Perla Abigail Alvarado-Vazquez

13 November 2017

0 references

0 references

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

E Alfonso Romero-Sandoval

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ashley L Kolano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

1 reference

5 October 2017

1 reference

Current Rheumatology Reports

13 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11926-017-0693-1

1 June 2020

exact match

0 references

cites work

Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017.

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Agonistic properties of cannabidiol at 5-HT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Vaporization as a smokeless cannabis delivery system: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Human cannabinoid pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

The abuse potential of the synthetic cannabinoid nabilone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabinoids for Medical Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Low-dose vaporized cannabis significantly improves neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Nabilone for the treatment of pain in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Effects of nabilone, a synthetic cannabinoid, on postoperative pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0693-1

Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28983880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11926-017-0693-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28983880%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference